Literature DB >> 32073535

Update of the position paper on arterial hypertension and erectile dysfunction.

Margus Viigimaa1,2, Charalambos Vlachopoulos3, Michael Doumas4, Jacek Wolf5, Konstantinos Imprialos4, Dimitios Terentes-Printzios3, Nikolaos Ioakeimidis3, Andres Kotsar6, Urmo Kiitam1,2, Konstantinos Stavropoulos4, Krzysztof Narkiewicz5, Athanasios Manolis7, Bojan Jelakovic8, Dragan Lovic9, Reinhold Kreutz10, Konstantinos Tsioufis3, Giuseppe Mancia11.   

Abstract

: Sexual health is an integral part of overall health, and an active and healthy sexual life is an essential aspect of a good life quality. Cardiovascular disease and sexual health share common risk factors (arterial hypertension, diabetes mellitus, dyslipidemia, obesity, and smoking) and common mediating mechanisms (endothelial dysfunction, subclinical inflammation, and atherosclerosis). This generated a shift of thinking about the pathophysiology and subsequently the management of sexual dysfunction. The introduction of phosphodiesterase type 5 inhibitors revolutionized the management of sexual dysfunction in men. This article will focus on erectile dysfunction and its association with arterial hypertension. This update of the position paper was created by the Working Group on Sexual Dysfunction and Arterial Hypertension of the European Society of Hypertension. This working group has been very active during the last years in promoting the familiarization of hypertension specialists and related physicians with erectile dysfunction, through numerous lectures in national and international meetings, a position paper, newsletters, guidelines, and a book specifically addressing erectile dysfunction in hypertensive patients. It was noted that erectile dysfunction precedes the development of coronary artery disease. The artery size hypothesis has been proposed as a potential explanation for this observation. This hypothesis seeks to explain the differing manifestation of the same vascular condition, based on the size of the vessels. Clinical presentations of the atherosclerotic and/or endothelium disease in the penile arteries might precede the corresponding manifestations from larger arteries. Treated hypertensive patients are more likely to have sexual dysfunction compared with untreated ones, suggesting a detrimental role of antihypertensive treatment on erectile function. The occurrence of erectile dysfunction seems to be related to undesirable effects of antihypertensive drugs on the penile tissue. Available information points toward divergent effects of antihypertensive drugs on erectile function, with diuretics and beta-blockers possessing the worst profile and angiotensin receptor blockers and nebivolol the best profile.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32073535     DOI: 10.1097/HJH.0000000000002382

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  9 in total

1.  Effects of Major Antihypertensive Drug Classes on Erectile Function: a Network Meta-analysis.

Authors:  Ioannis T Farmakis; Nikolaos Pyrgidis; Ioannis Doundoulakis; Ioannis Mykoniatis; Evangelos Akrivos; George Giannakoulas
Journal:  Cardiovasc Drugs Ther       Date:  2021-05-04       Impact factor: 3.947

Review 2.  Biology of iatrogenic sexual dysfunction in men and women survivors of cancer.

Authors:  Fernanda Priviero; Clinton Webb
Journal:  Urol Oncol       Date:  2021-02-07       Impact factor: 2.954

3.  Deterioration of Sexual Health in Cancer Survivors Five Years after Diagnosis: Data from the French National Prospective VICAN Survey.

Authors:  Lorène Seguin; Rajae Touzani; Anne-Déborah Bouhnik; Ali Ben Charif; Patricia Marino; Marc-Karim Bendiane; Anthony Gonçalves; Gwenaelle Gravis; Julien Mancini
Journal:  Cancers (Basel)       Date:  2020-11-20       Impact factor: 6.639

4.  MYPT1 reduction is a pathogenic factor of erectile dysfunction.

Authors:  Wei Zhao; Jie Sun; Liang-Yu Yao; Dong Hang; Ye-Qiong Li; Cai-Ping Chen; Yu-Wei Zhou; Xin Chen; Tao Tao; Li-Sha Wei; Yan-Yan Zheng; Xie Ge; Chao-Jun Li; Zhong-Cheng Xin; Yang Pan; Xin-Zhu Wang; Wei-Qi He; Xue-Na Zhang; Bing Yao; Min-Sheng Zhu
Journal:  Commun Biol       Date:  2022-07-25

Review 5.  Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs.

Authors:  Dimitrios Terentes-Printzios; Nikolaos Ioakeimidis; Konstantinos Rokkas; Charalambos Vlachopoulos
Journal:  Nat Rev Cardiol       Date:  2021-07-30       Impact factor: 32.419

6.  Protective effects of irbesartan and benazepril against vaginal vascular remodeling and fibrosis in female spontaneously hypertensive rats.

Authors:  Ruixin Ma; Yang Zhao; Xiaorong Yu; Ningyin Li; Qiongying Wang; Wei Liang; Xu Zhao; Jing Yu
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671

7.  The role of tadalafil in treated hypertensive patients with erectile dysfunction.

Authors:  Ehud Grossman
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-01-31       Impact factor: 3.738

8.  Pre and Postoperative Sexual Dysfunction in Patients with Leriche Syndrome-A Prospective Pilot Study.

Authors:  Michał Tkocz; Anna Brzęk; Mateusz Marcinek; Violetta Skrzypulec-Plinta; Damian Ziaja
Journal:  Int J Environ Res Public Health       Date:  2022-03-06       Impact factor: 3.390

9.  The effect of nebivolol on erectile function in the cases with coronary artery bypass surgery: A protocol for a systematic review and meta-analysis of randomized controlled trials.

Authors:  Yali Yang; Shanshan Yong; Fuhao Li; Liang Dong; Degui Chang
Journal:  Medicine (Baltimore)       Date:  2020-08-07       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.